Diabetes Management: Biocon, Mylan drug Kixelle gets positive opinion from European Medicines Agency
New Delhi: Biotechnology firm Biocon on Monday said its subsidiary Biocon Biologics and Mylan have received a positive opinion from the European Medicines Agency's committee for medicinal products for human use (CHMP) recommending approval of the market authorisation of their product 'Kixelle' use for the treatment of type 1 and 2 diabetes."Biocon Biologics and Mylan (a subsidiary of...
Login or Register to read the full article
New Delhi: Biotechnology firm Biocon on Monday said its subsidiary Biocon Biologics and Mylan have received a positive opinion from the European Medicines Agency's committee for medicinal products for human use (CHMP) recommending approval of the market authorisation of their product 'Kixelle' use for the treatment of type 1 and 2 diabetes.
"Biocon Biologics and Mylan (a subsidiary of Viatris Inc.) have received a positive opinion from the European Medicines Agency's committee for medicinal products for human use (CHMP) recommending approval of the market authorisation of Kixelle, a biosimilar Insulin Aspart, which is a rapid acting insulin for the treatment of type 1 and 2 diabetes," Biocon said in a regulatory filing.
Biocon said the CHMP positive opinion will be considered by the European Commission. The European Commission decision on the approval is expected early next year.
Christiane Hamacher, CEO, Biocon Biologics, said the company will look forward to a final decision from the European Commission approving Insulin Aspart "which will enable us to expand our offering to people with diabetes to include a rapid acting insulin analog along with a long acting insulin glargine".
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd